Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials


Ruperto N., Brunner H. I. , Quartier P., Constantin T., Wulffraat N. M. , Horneff G., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.77, ss.1710-1719, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 77 Konu: 12
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1136/annrheumdis-2018-213150
  • Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
  • Sayfa Sayıları: ss.1710-1719

Özet

Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).